Castle Biosciences, Inc.

NasdaqGM:CSTL Stock Report

Market Cap: US$522.5m

Castle Biosciences Management

Management criteria checks 2/4

Castle Biosciences' CEO is Derek Maetzold, appointed in Sep 2007, has a tenure of 16.58 years. total yearly compensation is $7.55M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 1.52% of the company’s shares, worth $7.96M. The average tenure of the management team and the board of directors is 3.7 years and 4 years respectively.

Key information

Derek Maetzold

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage8.7%
CEO tenure16.6yrs
CEO ownership1.5%
Management average tenure3.7yrs
Board average tenure4yrs

Recent management updates

Recent updates

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Castle Biosciences Q2 2022 Earnings Preview

Aug 08

Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?

Aug 05
Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?

Estimating The Intrinsic Value Of Castle Biosciences, Inc. (NASDAQ:CSTL)

Jun 06
Estimating The Intrinsic Value Of Castle Biosciences, Inc. (NASDAQ:CSTL)

CEO Compensation Analysis

How has Derek Maetzold's remuneration changed compared to Castle Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$57m

Sep 30 2023n/an/a

-US$76m

Jun 30 2023n/an/a

-US$89m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$8mUS$660k

-US$67m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$7mUS$625k

-US$31m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$5mUS$550k

-US$10m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

US$7m

Mar 31 2020n/an/a

US$6m

Dec 31 2019US$4mUS$770k

US$3m

Sep 30 2019n/an/a

US$4m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$791kUS$410k

-US$10m

Compensation vs Market: Derek's total compensation ($USD7.55M) is above average for companies of similar size in the US market ($USD2.36M).

Compensation vs Earnings: Derek's compensation has increased whilst the company is unprofitable.


CEO

Derek Maetzold (61 yo)

16.6yrs

Tenure

US$7,552,577

Compensation

Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...


Leadership Team

NamePositionTenureCompensationOwnership
Derek Maetzold
Founder16.6yrsUS$7.55m1.52%
$ 8.0m
Frank Stokes
CFO & Treasurer6.3yrsUS$2.61m0.15%
$ 773.2k
Kristen Oelschlager
Chief Operating Officer3.7yrsUS$2.70m0.55%
$ 2.9m
Tobin Juvenal
Chief Commercial Officer3.7yrsUS$2.70m0.18%
$ 953.8k
Camilla Zuckero
Vice President of Investor Relations & Corporate Affairsno datano datano data
Alice Izzo
Senior Vice President of Marketing6.1yrsno datano data
Kevin Doman
Vice President of Sales1.8yrsno datano data
Keli Greenberg
VP of Human Resources & Executive Director of Human Resources3.8yrsno datano data
Robert Cook
Senior Vice President of Research & Development3.6yrsno datano data
Matthew Goldberg
Senior Vice President of Medicalless than a yearno datano data
Bernhard Spiess
Company Secretaryno dataUS$1.69mno data

3.7yrs

Average Tenure

58yo

Average Age

Experienced Management: CSTL's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Derek Maetzold
Founder16.6yrsUS$7.55m1.52%
$ 8.0m
Daniel Bradbury
Independent Chairman of the Board11.6yrsUS$262.56k0.15%
$ 768.0k
G. Cole
Independent Director5.3yrsUS$248.56k0.017%
$ 88.1k
Tiffany Olson
Independent Director2.9yrsUS$238.56k0.026%
$ 137.9k
Mara Aspinall
Independent Director9.2yrsUS$241.06k0.13%
$ 672.4k
Kenneth Aldape
Member of Scientific Advisory Boardno datano datano data
Howard Colman
Member of Scientific Advisory Boardno datano datano data
Kimberlee Caple
Independent Director2.8yrsUS$236.06k0.017%
$ 89.1k
Miles Harrison
Independent Director4yrsUS$241.06k0.017%
$ 88.1k
Ellen Goldberg
Independent Director2.8yrsUS$233.56k0.034%
$ 180.0k
Rodney Cotton
Independent Directorless than a yearno datano data

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: CSTL's board of directors are considered experienced (4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.